Program
duvelisib
Also written as “Duvelisib”, “IPI-145” and “IPI-145 (duvelisib)”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma · Lymphoma, Follicular · Hematologic Neoplasms · Mycosis Fungoides, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| SecuraBio | 232 open or running | phase 3since Nov 13, 2013 | Nov 17, 2011 | Feb 2028phase 3 · NCT06522737 |
| AbbVie | 20 open or running | phase 1since Oct 21, 2015 | Oct 21, 2015 | none ahead |
| CSPC Pharmaceutical Group | 10 open or running | phase 2since Apr 24, 2020 | Apr 24, 2020 | none ahead |
Also a collaborator on its studies: Infinity Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Nov 17, 2011.
- Jul 25, 2014Phase 3 study in Lymphoma, FollicularSecuraBio · NCT02204982 · 13 enrolled · Australia, France, Italy and more
- Nov 10, 20142 phase 1 studiesSecuraBio · NCT02292225, NCT02307461
- Oct 7, 2015Phase 3 study in Lymphoma, FollicularSecuraBio · NCT02576275 · United States
- Oct 21, 2015AbbVie's first study: phase 1 study in LymphomaNew to AbbVieAbbVie · NCT02598570 · 7 enrolled · Japan
- Nov 4, 2015Phase 2 study in LymphomaSecuraBio · NCT02605694 · United States
- Dec 23, 2015Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT02640833 · United States
- Mar 15, 2016Phase 2 study in Hematologic NeoplasmsSecuraBio · NCT02711852 · 19 enrolled · United States, Italy
- Nov 29, 2017Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellSecuraBio · NCT03370185 · United States
- Dec 1, 2017Phase 2 study in Lymphoma, T-Cell, PeripheralSecuraBio · NCT03372057 · 156 enrolled · United States, Germany, Italy and more
- Jul 10, 2019Phase 2 study in Indolent Non-Hodgkin LymphomaSecuraBio · NCT04038359 · 103 enrolled · United States, Czechia, Germany and more
- Dec 4, 2019Phase 2 study in Squamous Cell Carcinoma of Head and NeckSecuraBio · NCT04193293 · 2 enrolled · United States
- Apr 24, 2020CSPC Pharmaceutical Group's first study: phase 2 study in Lymphoma, FollicularNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT04707079 · 24 enrolled · China
- Jul 22, 2024Phase 3 study in LymphomaSecuraBio · NCT06522737 · 124 planned · Belgium, Czechia, Denmark and more
- Jul 15, 2026Phase 1 study in Mycosis FungoidesSecuraBio · NCT07714187 · 30 planned · United States
Ahead
- Feb 2028Primary completion: phase 3 study in LymphomaSecuraBio · NCT06522737
- Oct 2028Primary completion: phase 1 study in Mycosis FungoidesSecuraBio · NCT07714187
TargetBeta
“PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| gedatolisibrule | Pfizer | phase 3 | 9 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07714187Mycosis Fungoides · United States | 1 | Not yet recruiting | SecuraBio | Oct 2028 | 30 |
| NCT06522737Lymphoma · Belgium, Czechia, Denmark and more | 3 | Recruiting | SecuraBio | Feb 2028 | 124 |
| NCT04707079Lymphoma, Follicular · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Oct 31, 2021 | 24 |
| NCT04193293Squamous Cell Carcinoma of Head and Neck · United States | 2 | Terminated | SecuraBio | Dec 10, 2020 | 2 |
| NCT04038359Indolent Non-Hodgkin Lymphoma · United States, Czechia, Germany and more | 2 | Completed | SecuraBio | Jul 24, 2023 | 103 |
| NCT03372057Lymphoma, T-Cell, Peripheral · United States, Germany, Italy and more | 2 | Completed | SecuraBio | Dec 22, 2023 | 156 |
| NCT03370185Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Withdrawn | SecuraBio | Jun 2020 | 0 |
| NCT02711852Hematologic Neoplasms · United States, Italy | 2 | Completed | SecuraBio | May 4, 2020 | 19 |
| NCT02640833Leukemia, Lymphocytic, Chronic, B-Cell · United States | 1 | Withdrawn | AbbVie | Jan 2020 | 0 |
| NCT02605694Lymphoma · United States | 2 | Withdrawn | SecuraBio | Nov 2016 | 0 |
| NCT02598570Lymphoma · Japan | 1 | Completed | AbbVie | Dec 2016 | 7 |
| NCT02576275Lymphoma, Follicular · United States | 3 | Withdrawn | SecuraBio | Nov 2016 | 0 |
| NCT02307461Healthy · United States | 1 | Completed | SecuraBio | Aug 2015 | 103 |
| NCT02292225Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada | 1 | Terminated | SecuraBio | Nov 2016 | 3 |
| NCT02204982Lymphoma, Follicular · Australia, France, Italy and more | 3 | Terminated | SecuraBio | Dec 2016 | 13 |
| NCT02095587Hepatic Impairment · United States | 1 | Completed | SecuraBio | Jul 2014 | 24 |
| NCT02049515Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Completed | SecuraBio | Jun 12, 2020 | 99 |
| NCT02004522Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Completed | SecuraBio | May 19, 2017 | 319 |
| NCT01947777Healthy · United States | 1 | Completed | SecuraBio | Nov 2013 | 14 |
| NCT01925911Healthy · United States | 1 | Completed | SecuraBio | Sep 2013 | 14 |
| NCT01882803Indolent Non-Hodgkin Lymphoma · United States, Belarus, Belgium and more | 2 | Completed | SecuraBio | Nov 18, 2020 | 129 |
| NCT01851707Arthritis, Rheumatoid · Bulgaria, Colombia, Germany and more | 2 | Completed | SecuraBio | Dec 2014 | 322 |
| NCT01836861Healthy · Netherlands | 1 | Completed | SecuraBio | Apr 2013 | 6 |
| NCT01653756Asthma · Germany, United Kingdom | 2 | Completed | SecuraBio | Aug 2014 | 50 |
| NCT01549106Healthy Volunteers · Netherlands | 1 | Completed | SecuraBio | Feb 2012 | 106 |
| NCT01476657Hematologic Neoplasms · United States | 1 | Terminated | SecuraBio | Dec 2016 | 210 |
How it is read
Names in the registry
- “Duvelisib”, 16 entries
- “IPI-145”, 9 entries
- “IPI-145 (duvelisib)”, 3 entries
- “IPI-145, a PI3K Inhibitor”, 1 entry
- “duvelisib”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 5 studies
- Lymphoma, 3 studies
- Lymphoma, Follicular, 3 studies
- Hematologic Neoplasms, 2 studies
- Mycosis Fungoides, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.